453 related articles for article (PubMed ID: 29690611)
1. The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.
Xu P; Zhai Y; Wang J
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690611
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
3. The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome.
Pu S; Wu X; Yang X; Zhang Y; Dai Y; Zhang Y; Wu X; Liu Y; Cui X; Jin H; Cao J; Li R; Cai J; Cao Q; Hu L; Gao Y
Curr Drug Metab; 2019; 20(1):15-22. PubMed ID: 29886826
[TBL] [Abstract][Full Text] [Related]
4. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.
Dixon ED; Nardo AD; Claudel T; Trauner M
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33926085
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.
Cariello M; Piccinin E; Moschetta A
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1519-1539. PubMed ID: 33545430
[TBL] [Abstract][Full Text] [Related]
6. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of constitutive androstane receptor and its cross talk with liver X receptors and peroxisome proliferator-activated receptor A in lipid metabolism.
Xiao L; Wang J; Jiang M; Xie W; Zhai Y
Vitam Horm; 2013; 91():243-58. PubMed ID: 23374719
[TBL] [Abstract][Full Text] [Related]
8. Integration of metabolism and inflammation by lipid-activated nuclear receptors.
Bensinger SJ; Tontonoz P
Nature; 2008 Jul; 454(7203):470-7. PubMed ID: 18650918
[TBL] [Abstract][Full Text] [Related]
9. Gaining weight: the Keystone Symposium on PPAR and LXR.
Lehrke M; Pascual G; Glass CK; Lazar MA
Genes Dev; 2005 Aug; 19(15):1737-42. PubMed ID: 16077002
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
Hansen MK; Connolly TM
Curr Opin Investig Drugs; 2008 Mar; 9(3):247-55. PubMed ID: 18311660
[TBL] [Abstract][Full Text] [Related]
11. Activation of Liver X Receptors and Peroxisome Proliferator-Activated Receptors by Lipid Extracts of Brown Seaweeds: A Potential Application in Alzheimer's Disease?
Martens N; Zhan N; Voortman G; Leijten FPJ; van Rheenen C; van Leerdam S; Geng X; Huybrechts M; Liu H; Jonker JW; Kuipers F; Lütjohann D; Vanmierlo T; Mulder MT
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447330
[TBL] [Abstract][Full Text] [Related]
12. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
[TBL] [Abstract][Full Text] [Related]
13. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.
Li AC; Glass CK
J Lipid Res; 2004 Dec; 45(12):2161-73. PubMed ID: 15489539
[TBL] [Abstract][Full Text] [Related]
14. PPARs and other nuclear receptors in inflammation.
Rizzo G; Fiorucci S
Curr Opin Pharmacol; 2006 Aug; 6(4):421-7. PubMed ID: 16777482
[TBL] [Abstract][Full Text] [Related]
15. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism.
Xiao L; Xie X; Zhai Y
Adv Drug Deliv Rev; 2010 Oct; 62(13):1316-21. PubMed ID: 20659512
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity.
Barish GD
J Nutr; 2006 Mar; 136(3):690-4. PubMed ID: 16484544
[TBL] [Abstract][Full Text] [Related]
17. Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation.
Yue L; Ye F; Gui C; Luo H; Cai J; Shen J; Chen K; Shen X; Jiang H
Protein Sci; 2005 Mar; 14(3):812-22. PubMed ID: 15722453
[TBL] [Abstract][Full Text] [Related]
18. PPARs: therapeutic targets for metabolic disease.
Berger JP; Akiyama TE; Meinke PT
Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
[TBL] [Abstract][Full Text] [Related]
19. Orphan nuclear receptors find a home in the arterial wall.
Laffitte BA; Tontonoz P
Curr Atheroscler Rep; 2002 May; 4(3):213-21. PubMed ID: 11931719
[TBL] [Abstract][Full Text] [Related]
20. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
